Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
P49862

UPID:
KLK7_HUMAN

ALTERNATIVE NAMES:
Serine protease 6; Stratum corneum chymotryptic enzyme

ALTERNATIVE UPACC:
P49862; A8K0U5; Q8N5N9; Q8NFV7

BACKGROUND:
Kallikrein-7, identified by its alternative names Serine protease 6 and Stratum corneum chymotryptic enzyme, is integral to the natural exfoliation process of the skin, facilitating the breakdown of intercellular bonds in the outermost skin layer. Its specificity for aromatic amino acids in the P1 position and ability to cleave insulin A and B chains underscore its importance in the activation of inflammatory cytokine precursors.

THERAPEUTIC SIGNIFICANCE:
The exploration of Kallikrein-7's function offers a promising avenue for therapeutic intervention, especially in dermatological conditions and inflammation management. By targeting the enzymatic pathways of Kallikrein-7, new therapeutic modalities could be developed to enhance skin health and control inflammatory responses.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.